Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID06865222

Variable Pulse Transcranial Magnetic Stimulation for Treatment of Post COVID Syndrome

Led by Mayo Clinic · Updated on 2025-08-14

40

Participants Needed

1

Research Sites

12 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating Variable Pulse Transcranial Magnetic Stimulation (TMS) to see if it can improve symptoms in patients with Post COVID Syndrome (PCS), including anosmia, tinnitus, and fatigue. This study is sponsored by Mayo Clinic and focuses on adults aged 18 to 65 who have ongoing symptoms lasting more than 4 weeks after a confirmed COVID-19 infection. The study aims to measure changes in smell, tinnitus, and fatigue scores as primary outcomes to assess treatment effects. The treatment involves an Electromagnetic Brain Pulsing Variable Pulse Protocol (EMBP) delivered using an FDA-approved TMS device. Participants will receive one 30-minute TMS session per day, five days a week (Monday through Friday), for either 2 weeks or 4 weeks, depending on the assigned group. Baseline EEG results will guide personalized TMS parameters for each participant. The study has three groups based on specific symptoms: anosmia, tinnitus, and fatigue. Participants will undergo evaluations including smell identification tests, tinnitus impact scales, fatigue scales, anxiety and depression questionnaires, and EEG measurements at various points during and after treatment. Safety will be monitored for up to two years, tracking serious adverse events. The study duration includes multiple assessments at baseline, 1 to 12 weeks after treatment, and extended follow-up to understand long-term effects.

CONDITIONS

Brief Title

Post COVID-19 Syndrome Treatment With Variable Pulse Transcranial Magnetic Stimulation

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a recent COVID-19 infection attending the Post COVID-19 Clinic with at least one symptom: anosmia, tinnitus, or fatigue
  • Symptoms consistent with Post COVID Condition lasting more than 1 month after the positive COVID test
  • Ongoing symptoms for more than 4 weeks following acute COVID infection
  • Anosmia confirmed by Olfactory Threshold Test scores indicating anosmia or hyposmia
  • Tinnitus with a score above 0 on the Tinnitus Handicap Inventory, not present before COVID infection
  • Fatigue with a Modified Fatigue Impact Scale score of 40 or higher
Not Eligible

You will not qualify if you...

  • Having implanted electronic devices such as pacemakers, defibrillators, implant medication pumps, or vagus nerve stimulators
  • Active alcohol abuse (more than 14 drinks per week or formal diagnosis), illicit drug use, or drug abuse
  • History of seizures within the past 10 years
  • Intracranial implants or metal objects near the head that cannot be safely removed
  • Currently enrolled or planning to enroll in another interventional trial
  • Previous stroke with residual deficits
  • Unable to understand or follow verbal commands
  • Unable to comprehend and sign informed consent
  • Medical conditions preventing tolerance of trial procedures as assessed by physicians
  • Clinically unstable or abnormal medical conditions posing safety risks
  • Pregnant or trying to become pregnant; negative pregnancy test required for females of childbearing potential
  • Any condition that may prevent study completion as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 2 to 4 weeks

Participants receive daily 30-minute Transcranial Magnetic Stimulation sessions, 5 days a week (Monday to Friday), for either 2 or 4 weeks depending on their assigned group.

Daily visits, 5 days per week

Follow-up

Duration - Up to 12 weeks after treatment

Participants are monitored to assess changes in symptoms and safety after completing the treatment.

Visits at 10 to 12 weeks post-baseline

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

D

Department of Medicine Research Hub, Coordinator

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Similar Trials

Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients: A ...

Post COVID-19 Condition

Actively Recruiting

1 location

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Trea...

Post COVID-19 Condition

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here